Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Andrea Pirzkall"'
Autor:
Costantine Albany, Andrea Pirzkall, Michael Chisamore, Jennifer Visich, Elizabeth I Buchbinder, Xiaohan Liu, David R Spigel, Kelly D Moynihan, Christopher DelNagro, Matt Axt, Mark Sayles
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d71c8f8460c0414cb01afc953fb43ffa
Autor:
Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Jason Chesney, Mohammed Milhem, Kevin Harrington, Robert Coffin, Katy Tsai, Adel Samson, Bartosz Chmielowski, Ari VanderWalde, Andrea Pirzkall, Jiaxin Niu, Praveen Bommareddy, Georgia Beasley, Gino In, Terence Rhodes, Francesca Aroldi, Lavita Menezes, Tawnya Bowles, Hamid Emamekhoo, Scott Baum, Sophie Dalac-Rat, Katharina Kahler, Eva Muñoz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d5df803646ea41a1b37a9be032989313
Autor:
Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Andrea Pirzkall, Praveen Bommareddy, Isla Leslie, Francesca Aroldi, Pablo Nenclares, Tze Chan, Imran Saleem, Henry Castro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d1aa5ab6afc849d2b95d01f6b52502df
Autor:
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, N
Externí odkaz:
https://doaj.org/article/fa3f41ad888d41f5a1c759f8b6fa21b2
Autor:
Sophie Dalac-Rat, Anna Olsson-Brown, Jiaxin Niu, Praveen K. Bommareddy, Francesca Aroldi, Katy K. Tsai, Terence Duane Rhodes, Robert S. Coffin, Katharina C. Kähler, Adel Samson, Tawnya L. Bowles, Mohammed M. Milhem, Gino K. In, Bartosz Chmielowski, Eva Muñoz, Georgia M. Beasley, Joseph J. Sacco, Scott Baum, Kevin J. Harrington, Mark R. Middleton, Lavita Menezes, Hamid Emamekhoo, Jason Chesney, Andrea Pirzkall, Ari M. Vanderwalde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP1 is an enhanced potency oncolytic HSV-1 which expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM-CSF).1 In pre-clinical studies, RP1 demonstrated potent GALV-GP R-enhanced anti-tumor
Autor:
Pablo Nenclares, Praveen K. Bommareddy, Kevin J. Harrington, Anna Olsson-Brown, Henry Castro, Joseph J. Sacco, Tze Chan, Robert S. Coffin, Imran Saleem, Mark R. Middleton, Francesca Aroldi, Andrea Pirzkall, Isla Leslie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP2 is a first-in-class, enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being tested in an open-label, multicenter, phase 1 stu
Autor:
Claire F. Verschraegen, Susan Navia, Andrea Pirzkall, Andrew Poklepovic, Jason J. Luke, Frances A. Collichio, Praveen K. Bommareddy, Wanxing Chai-Ho, Diana Bolotin, Michael R. Migden, Robert S. Coffin, Henry Castro, Trisha Wise-Draper, Katy K. Tsai, Douglas Earl Laux, Gregory A. Daniels, Meenal Kheterpal, Jose Lutzky
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A580-A580
BackgroundSolid organ transplantation (SOT) has emerged as an important lifesaving procedure for patients with a wide range of end-organ diseases characterized by dysfunction or specific organ function failure. SOT rejection is a major complication r
Autor:
Mario R. Mautino, Ray S. Lin, John Edward Janik, Eugene P. Kennedy, Andrea Pirzkall, Charles J. Link, Xiaorong Liang, David H. Munn, Sami Mahrus, Bruce McCall, Nicholas N. Vahanian, Laurent Salphati, Zhonglin Hao, Stephanie Royer-Joo, Asha Nayak-Kapoor, Samir N. Khleif, Lisa Marshall, Ramses F. Sadek, W. Jay Ramsey, Kari M. Morrissey, Robin Dobbins
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i
Autor:
Sami Mahrus, Jing Peng, Erik L. Brincks, Mario R. Mautino, Mark Merchant, Liling Liu, Stephanie Dale, Elizabeth Jones, Sheerin Latham, Andrea Pirzkall, Jessica Spahn, Edward Lorenzana, Thomas Hunsaker, Kevin DeMent, Ehud Segal, Laurent Salphati, Cristine Quiason, Yichin Liu, Georgia Hatzivassiliou, David Kan, Sean K. Kelley
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Indoleamine 2, 3-dioxygenase (IDO1) is a cytosolic enzyme catalyzing the oxidation of tryptophan to kynurenine. IDO1 plays an important role in modulating immune responses in cancer, where increasing evidence suggests that IDO1 expr